reported inconsistency between two large-scale pharmacogenomic studies-the Cancer Cell Line Encyclopedia (CCLE) 2 and the Cancer Genome Project (CGP) 3 . Upon careful analysis of the same data, we have come to quite different and much more positive conclusions. Here we highlight the most important reasons for this. There is a Reply to this Comment by Safikhani, Z. et al. Nature 540, http://dx.doi.org/10.1038/nature19839 (2016) .
To assess the concordance of two large studies of the efficacy of cancer drugs, Haibe-Kains et al. 1 compared the correlation in drug sensitivity measures with correlation in gene expression measured on the same human cancer cell lines. The authors reported correlation 'between' cell lines for gene expression but, inconsistently, 'across' cell lines for drug sensitivity (see Methods). On re-analysis, we found much higher correlations between cell lines than across cell lines for both gene expression and drug sensitivity measures (median Spearman's rank correlation coefficient (r s ) = 0.88 between cell lines, r s = 0.56 across cell lines for expression; median r s = 0.62 between cell lines and r s = 0.35 across cell lines for area under the curve (AUC), a drug sensitivity measure). Thus, by correcting this inconsistency, the correlations for expression and drug sensitivity data were far more similar than was originally reported, which markedly undermines the authors' interpretation of the relative quality of expression and drug sensitivity datasets.
In addition, the fundamental issue is that the authors' reported Spearman's correlation coefficients do not fairly reflect the concordance of drug sensitivity between the studies, because of the lack of variability in drug response, which arises owing to the highly targeted nature of many of the drugs assessed. To see why correlation is not an appropriate measure of biological concordance for these data, consider the hypothetical example of a drug that is not effective against any cell lines, which is a possibility for an experimental drug. In such a case, the randomly fluctuating measurement error, which is inherent in biological assays, will dominate over the non-existent biological variability, meaning that there could be no expectation of correlation between repeated measures of drug sensitivity-assuming other experimental variables are held constant. In this study, many of the drugs were highly targeted agents, which by design require specific, and often rare, molecular targets for response (see Supplementary Table 1) . Consider nilotinib, which targets the BCR-ABL1 fusion gene and was suggested in ref. 1 to exhibit 'poor consistency' between CGP and CCLE (r s = 0.1 for AUC). In CGP, BCR-ABL1 status was reported to be strongly associated with drug sensitivity (P = 2.54 × 10 −65 ), accurately reflecting the known biology. BCR-ABL1 status was not reported by CCLE; however, upon re-analysis we identified three BCR-ABL1-positive cell lines among the 189 nilotinib-treated cell lines that overlapped CGP, and these were also the three most sensitive samples (P = 9 × 10
−7
). Hence, despite the fact that these drug sensitivity data were accurately recapitulating biological expectations in both studies, the authors' criteria classified nilotinib sensitivity incorrectly. Of the 577 cell lines screened in CGP, 573 do not contain the nilotinib target, that is, the BCR-ABL1 fusion gene. Thus, given (as expected) no drug response in almost all cell lines screened (median AUC across all cell lines = 0.99; AUC of 1 represents no drug response; Fig. 1a, Supplementary Table 1) , there was little biological variability across most of the cell lines, resulting in low correlation between the repeated measurements made by CCLE and CGP, despite clearly concordant results. Similarly, most other drugs that the authors compared were also targeted agents, meaning that this lack of drug response was common; for 10 of the 15 drugs, the median AUC was greater than 0.90 in CGP, and 8 of these 10 also have median AUC values greater than 0.9 in CCLE, resulting in little variability across most cell lines when treated with these drugs. We identified a systematic relationship between variability in drug response in either study and correlation between the two studies (Fig. 1b) . A valid comparison of CGP and CCLE should consider the pharmacology of the drugs screened and in particular the differences in the variability induced by different drugs. Nilotinib was not an isolated case; despite the highly experimental nature of many of the compounds screened by CCLE and CGP, we still identified several expected associations that were consistently reported by both studies, including ERBB2 for lapatinib 4 , NQO1 expression for 17-AAG 5 , BRAF mutation for PD-0325901 (ref. Table 1 ). Finally, the utility of these pharmacogenomic datasets is now further supported by the findings that models fit using data from CGP could reliably predict drug response in several clinical trials 11, 12 . In summary, our analysis shows that the conclusions of Haibe-Kains et al. 1 are unsubstantiated, and we propose that a fair assessment of concordance between large pharmacogenomic datasets will require the development or adaptation of methods that account for the issues raised here, although great care will be required to ensure that such methods do not introduce their own unforeseen biases.
Methods
In CGP and CCLE, using ordered data common to both studies, gene expression and drug sensitivity (AUC) values can be arranged in n 1 × m and n 2 × m matrices, respectively, in which m is the number of cell lines, n 1 is the number of genes and n 2 is the number of drugs common to both studies. Correlations 'between' cell lines are calculated by the correlation of matching columns of CGP and CCLE matrices (vectors of length n 1 for expression or n 2 for AUC). Correlations 'across' cell lines are the correlations of matching rows (vectors of length m for both data).
To achieve easy reproduction of our results, we have made the source code for our analysis available in a GitHub repository (https://github.com/paulgeeleher/ nature_bca).
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Geeleher and colleagues 1 raise two potential issues with our published study 4 and we welcome the opportunity to address them here. First, in our initial study, we computed the correlation of gene expression and mutation profiles between cell lines to assess whether large transcriptomic changes and/or genetic drift might be the cause of the observed inconsistency in drug sensitivity data (which was calculated across cell lines) 4 . We agree with Geeleher et al. 1 that correlations 'across' and 'between' cell lines should be compared in a consistent manner, as was done in our recent re-analysis study 5 . We found that overall correlation across cell lines is lower than correlation between cell lines (Supplementary Fig. 2) . However, gene expression data are significantly more concordant between studies than the drug response summary statistics (half-maximum inhibitory In the accompanying Comment 1 , Geeleher et al. claim to have discovered overall consistency between the Cancer Genome Project (CGP) 2 and the Cancer Cell Line Encyclopedia (CCLE) 3 by analysing the response of three cell lines containing the BCR-ABL1 fusion gene to the highly targeted drug nilotinib (Supplementary Fig. 1 ). They use this example to argue that owing to the targeted nature of many of the 15 drugs screened in both CGP and CCLE (Supplementary Table 1) , the rest of the drugs should show consistent sensitivity measurements if analysis is limited to the highly sensitive cell lines. However, as we describe in more detail below, the consistency seen in the sensitivities of cell lines to nilotinib is an isolated example that does not generalize to other targeted drugs, supporting our initial finding 4 of a broader inconsistency in reported phenotypes between CGP and CCLE concentration (IC 50 ) and area under the curve (AUC)) values in all comparisons (Wilcoxon rank sum test P < 0.002). Consequently, our original conclusion that gene expression data are significantly more correlated than pharmacological response data still holds. In fact, the lower correlation of gene expression values across cell lines could suggest that there is even less consistency between the CCLE and CGP studies than we initially reported.
Paul Geeleher
Second, the argument of Geeleher et al. 1 that the lack of variability in drug sensitivity measurements may complicate biologically meaningful assessment of concordance between pharmacogenomic datasets is not new, as it was already discussed by our group 5 and others 6, 7 . Geeleher et al. 1 focus on the sole example of nilotinib, for which there are three highly sensitive cell lines out of the 200 cell lines screened in both datasets. However, even among these three cell lines, the AUC values are not concordant; the least sensitive of the three cell lines in CGP is actually the most sensitive one in CCLE ( Supplementary Fig. 1 and Supplementary Information) . Therefore, the only way to consider these results to be concordant is to classify these three cell lines as sensitive and the remainder as resistant, which cannot easily be done using the waterfall method described in the CCLE study 3, 4 . The authors claim that nilotinib is not an isolated example 1 , but do not seem to propose any statistic to quantify the consistency of the other drugs. We adapted the Matthews correlation coefficient 8 (AMCC; see Supplementary Methods) to select the optimal cutoff for consistency between drug sensitivity calls, in which only a few cell lines may be sensitive, or between gene expression data, in which the gene of interest may be rarely expressed. As expected, nilotinib yielded an AMCC value of 1, which denotes perfect consistency between the two studies ( Supplementary Fig. 3 ). However, the other drugs yielded much lower AMCC values, with only AZD0530, lapatinib and critozinib yielding AMCC values of around 0.65, with another five drugs (17-AAG, AZD6244, erlotinib, PD-0325901 and PLX4720) yielding moderate consistency (0.5 ≤ AMCC < 0.6), and the rest of the drugs yielding poor consistency (AMCC < 0.5). Notably, there was no systematic relationship between variability in drug sensitivity and AMCC estimates (Supplementary Figs 4 and 5) , suggesting that AMCC values, although potentially overoptimistic, are a more appropriate statistic for consistency than Spearman's or Pearson's correlation coefficients. It should be noted that the inter-laboratory replicates of the measurements of camptothecin and AZD6482 sensitivity performed using the same experimental protocols at two different locations within CGP yielded AMCC values of only 0.55 and 0.41 ( Supplementary  Fig. 6 ), indicating a lack of reproducibility of drug phenotype measures between biological replicates. Consistent with our previous report, gene expression data yielded significantly larger AMCC than drug sensitivity data across cell lines (Wilcoxon rank sum test P < 0.006; Supplementary  Fig. 7 ). This re-analysis confirms that nilotinib is an anecdotal case, and that drug sensitivity measurements for the rest of the drugs (cytotoxic or targeted) remain only poorly to moderately consistent.
Geeleher et al. 1 also state that their previous findings 9 support the utility of the data from the CCLE and CGP, and suggest that their findings provide evidence for a consistency between CGP and CCLE. However, a true test of this assertion would be to train their models on the CGP and to use these to predict phenotypes reported by CCLE (and vice versa). If they could predict the drug response phenotype in the independent validation set with high accuracy, this would provide some quantitative evidence of a consistency between the two datasets in the context of their predictive models 1 . However, we 10 and others [11] [12] [13] have shown that such an analysis does not yield robust predictions for most drugs.
In our original report 4 , we found statistically significant non-zero correlations between phenotype measurements for almost all drugs, supporting the fact that there is biologically relevant signal in these datasets, albeit confounded by significant noise. Concurring with recent reports 6, 7, 14 , we identified known gene-drug associations that are reproducible between CGP and CCLE (Supplementary Information); however, half of the known associations were inconsistent across datasets (significant in only one dataset; Supplementary Table 2) . In a recent re-analysis of the updated CGP and CCLE datasets, we reported that the discovery of new, potentially weaker biomarkers, which was the main goal of the CGP and CCLE studies, was much more challenging owing to inconsistency in pharmacological phenotypes 5 . In our original conclusions 4 , we argued that additional work is necessary to improve the consistency of phenotypic measures with the ultimate goal of making data from these large-scale projects more useful for development of robust predictors of drug response, and we believe that this conclusion still holds upon our re-analysis. We and others are actively working on identifying stable measures that could lead to improved consistency across inter-laboratory experiments.
Like Geeleher et al.
1
, we originally hoped to use the CCLE and CGP to develop robust biomarkers that could predict responses to treatment. Although we could use methods to find some consistency in selected subsets of the data, we found no general methods that identified an overall consistency between the studies. Geeleher et al. 1 have shown that if the drug sensitivity data are appropriately discretized, consistency can be found for nilotinib-but not for the other compounds tested in both studies. Despite the single example of nilotinib, we conclude as we did originally, that sensitivity phenotypes lack consistency for most of the drugs screened both in CGP and CCLE.
The methods are described in details in the Supplementary Information. The PharmacoGx package is open-source and publicly available on Bioconductor (https://bioconductor.org/packages/ PharmacoGx/). The the code and associated files required to reproduce this analysis are publicly available on the cdrug-rebuttals GitHub repository (https://github.com/bhklab/cdrug-rebuttals). The procedure to setup the software environment and run our analysis pipeline is provided in Supplementary Information. This work complies with the guidelines proposed previously 15 in terms of code availability and replicability of results.
Author A. C. Jin was a student in A.H.B. 's laboratory and left shortly after publication of ref. 4 , and did not participate in in the writing of this Reply. Authors Z.S., P.S. and M.F. developed the PharmacoGx software package, which enabled the analyses presented here; A.G. helped with the development of the AMCC statistics, and participated in the interpretation of the results and writing of this Reply. 
